As such, tankyrases are promising candidate targets for anti-cancer molecular therapies [19], and they hold particular promise for HCC since their over-expression has been previously detected under the pathogenic conditions of cancer, tissue fibrosis, and viral infection [20]. The gene discussed is TNKS; the disease is hepatocellular carcinoma.